Indeed, efforts have been directed to block PRL as a therapeutic avenue in breast cancer, including the generation of PRL antagonists (Del1-9-G129R-hPRL, G129R-Prl) [79, 80] and PRLR antagonist (LFA102) [81, 82]. This evidence concerns the gene PRL and breast carcinoma.